因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INCY 因塞特医疗

盘前交易 08-12 04:31:26 EDT

121.07

-0.48

-0.39%

最高122.28	最低120.06	成交量108.01万
今开121.13	昨收121.55	日振幅1.83%
总市值245.41亿	流通市值201.82亿	总股本2.03亿
成交额1.31亿	换手率0.65%	流通股本1.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":121.07,"timestamp":1786478400000,"preClose":121.55,"halted":0,"volume":1080064,"delay":0,"changeRate":-0.003948992184286335,"floatShares":166693112,"shares":202697746,"eps":7.85,"marketStatus":"盘前交易","change":-0.48,"latestTime":"08-12 04:31:26 EDT","open":121.13,"high":122.28,"low":120.0588,"amount":130692836.50176,"amplitude":0.018274,"askPrice":134.55,"askSize":100,"bidPrice":118.51,"bidSize":72,"shortable":3,"etf":0,"ttmEps":7.85,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786541400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":121.07,"postHourTrading":{"tag":"盘后","latestPrice":121.07,"preClose":121.07,"latestTime":"19:52 EDT","volume":59994,"amount":7263542.53,"timestamp":1786492338399,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.589777103643592,"impliedVol":0.3229,"impliedVolPercentile":0.196},"requestUrl":"/m/hq/s/INCY/wiki","defaultTab":"wiki","newsList":[{"id":"1170637857","title":"欧盟批准Opzelura®（芦可替尼）乳膏：首款无类固醇外用JAK抑制剂问世，专治成人中度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1170637857","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170637857?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:01","pubTimestamp":1785319274,"startTime":"0","endTime":"0","summary":"重大突破！欧盟正式批准Opzelura®（芦可替尼）乳膏上市。这款无类固醇外用JAK抑制剂，成为该地区首款用于成人中度特应性皮炎患者的同类创新药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4139","INCY","IDNA","BK4550","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132857824","title":"异动解读｜因塞特医疗盘中上涨5.24%，Q2业绩大幅超预期并上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1132857824","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132857824?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:42","pubTimestamp":1785249776,"startTime":"0","endTime":"0","summary":"7月28日，因塞特医疗盘中上涨5.24%，报125.455美元/股，成交额1.23亿美元。消息面上，公司于盘前发布第二季度财报，业绩大幅超出市场预期。核心驱动来自湿疹药膏Opzelura相关医疗补助回扣问题与CMS达成和解，预计为全年净销售额增加3亿至3.1亿美元，同时确认2.46亿美元一次性非现金收益。第二季度净销售额同比增长40%，达14.9亿美元。公司已上调全年营收指引以反映和解协议影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100439029","title":"异动解读 | 因塞特医疗盘中大涨5.04%，Q2业绩超预期并上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1100439029","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100439029?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:04","pubTimestamp":1785247466,"startTime":"0","endTime":"0","summary":"因塞特医疗今日盘中股价大涨5.04%，引发市场广泛关注。受湿疹药膏Opzelura相关医疗补助计划回扣问题与美国医疗保险和医疗补助服务中心达成和解的推动，因塞特医疗第二季度净销售额同比增长40%，达到14.9亿美元。据悉，因塞特医疗于6月就Opzelura的回扣标准与CMS达成和解协议，预计将为该药物2026年全年净销售额增加3亿至3.1亿美元。此次和解相关的2.46亿美元一次性非现金收益也对季度业绩形成了有力支撑。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164470622","title":"财报前瞻｜因塞特医疗本季度营收预计增24.55%，机构看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1164470622","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164470622?lang=zh_cn&edition=full","pubTime":"2026-07-21 09:35","pubTimestamp":1784597728,"startTime":"0","endTime":"0","summary":"因塞特医疗将于2026年07月28日美股盘前发布财报，市场关注Opzelura的最新进展与全年指引更新。市场一致预期本季度公司营收约14.34亿美元，同比增长24.55%，调整后每股收益约2.06美元，同比增长40.40%；公司方面此前披露将于本次财报更新全年指引以反映和解相关影响，当前未见明确的季度收入与利润目标。鉴于公开渠道尚未提供当季毛利率与净利润或净利率的主流预测，相关指标暂不展示。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜因塞特医疗本季度营收预计增24.55%，机构看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652152322","title":"Halozyme(HALO)与Incyte(INCY)联合推进创新药INCA033989皮下注射剂型开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652152322","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652152322?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:59","pubTimestamp":1784552369,"startTime":"0","endTime":"0","summary":"双方将利用Halozyme专有的ENHANZE药物递送技术，共同推进Incyte旗下在研创新药INCA033989皮下注射剂型的开发。根据协议条款，Halozyme将从Incyte获得一笔首付款，并有资格在未来达成特定开发及商业化里程碑时获得追加付款。此外，Halozyme还将根据使用ENHANZE技术药物的未来净销售额抽取一定比例的特许权使用费。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBBQ","MEDX","BK1161","LU0053671581.USD","BK4532","06978","INCY","BK1574","BK4588","IDNA","BK4585","159992","BK4550","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165004523","title":"奥洛兹美医疗与因塞特医疗达成全球合作与许可协议，利用Enhanze®技术开发皮下制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1165004523","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165004523?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:08","pubTimestamp":1784549338,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布，已与因塞特医疗签署了一项全球合作与许可协议。该协议旨在利用奥洛兹美医疗的Enhanze®技术，支持因塞特医疗旗下在研药物Inca033989开发皮下注射剂型。\n此次合作将结合双方的专业优势，探索通过皮下给药途径提升治疗便利性与患者体验的可能性。Enhanze®技术平台能够帮助大分子药物实现快速、高效的皮下递送。\n协议的达成标志着两家公司在创新药物递送解决方案领域的战略协同。此举有望为患者带来更便捷的治疗选择，并拓展相关技术的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","HALO","IDNA","BK4588","BK4550","BK4139","INCY","BK4532","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168121593","title":"奥洛兹美医疗与因塞特医疗达成协议，授予其Mutcalr项目Enhanze技术开发权及两项额外靶点选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1168121593","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168121593?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:04","pubTimestamp":1784549047,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗宣布，已授予生物制药公司因塞特医疗一项关键许可。根据协议，因塞特医疗将获得使用奥洛兹美医疗专有的Enhanze药物递送技术，以开发其Mutcalr项目的权利。此项合作不仅限于单一靶点，因塞特医疗同时还获得了两项额外靶点的选择权，为未来更广泛的管线开发铺平了道路。Enhanze技术旨在通过提高皮下给药的效率和便利性，优化生物制剂的给药方式。此次授权进一步拓展了Enhanze技术的应用范围，并强化了奥洛兹美医疗在合作开发领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4139","INCY","IDNA","LU0053671581.USD","HALO","BK4550","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122535319","title":"因塞特医疗公布Latarcibart一期/二期数据，显示对血管性血友病患者显著减少出血","url":"https://stock-news.laohu8.com/highlight/detail?id=1122535319","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122535319?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:03","pubTimestamp":1783929781,"startTime":"0","endTime":"0","summary":"因塞特医疗近日公布了其候选药物Latarcibart的一期/二期临床试验数据。数据显示，该药物在治疗血管性血友病（VWD）患者方面展现出令人鼓舞的疗效，能够显著减少患者的出血事件。\n此次公布的数据突显了Latarcibart在控制这类出血性疾病方面的潜力。试验结果表明，接受治疗的患者出血频率大幅降低，这为改善患者的生活质量带来了新的希望。该药物的作用机制旨在针对疾病根源，提供一种新的治疗选择。\n目前，针对血管性血友病的有效治疗方案仍然有限。Latarcibart的积极数据若能在后续更大规模的临床试验中得到验证，将有望填补这一领域的医疗需求。公司将继续推进该药物的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4585","IDNA","INCY","BK4139","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649858622","title":"Incyte(INCY)以12.5亿美元完成收购Vega Therapeutics 拓宽血液学管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2649858622","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649858622?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:19","pubTimestamp":1783343950,"startTime":"0","endTime":"0","summary":"根据双方此前达成的股票购买协议，Incyte已支付12.5亿美元的预付款，收购了Vega Therapeutics的全部发行在外股份。此外，Star Therapeutics未来还有权获得最高达7.5亿美元的商业销售里程碑付款。通过本次收购，Incyte成功将Vega的核心资产——创新单克隆抗体VGA039收入囊中。目前，该药物正在全球开展一项名为VIVID-6的单臂交叉3期临床试验，以评估其在各类血管性血友病患者中的安全性和有效性。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTkwMTRiMmRhYjljZTk4MGRjMGViZTQ1NDI1NzQxMTc4OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302236","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","INCY","LENZ","BK4007","IDNA","BK4139","BK4550","BK4539","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143206979","title":"一周美股牛榜 | Bio-Techne上周飙涨逾22%，艾伯维公司劲升逾17%，联合大陆航空涨超15%，康宁涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143206979","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143206979?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:18","pubTimestamp":1782699520,"startTime":"0","endTime":"0","summary":"默克提出每股73美元的收购要约后，Bio-Techne股价本周上涨22.5%，较该公司周三收盘价溢价24%。艾伯维斥资109亿美元收购Apogee，强化免疫学领域战略艾伯维股价本周上涨17%。联合大陆航空股价上涨，油价下跌和分析师看涨情绪提振航空股本周，联合大陆航空股价上涨15%。为了进一步提升股东价值，康宁董事会宣布派发每股0.28美元的季度股息。股息将于9月29日支付给截至8月31日登记在册的股东。","market":"us","thumbnail":"https://static.tigerbbs.com/98882962e3042a24d8295da8457c9db5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/98882962e3042a24d8295da8457c9db5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY","GLWG","ABBV","UAL","INCY","GLW","TECH","IQV","CRL"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1195131681","title":"异动解读｜因塞特医疗盘中上涨5.84%，Opzelura获欧盟CHMP积极意见推动股价走高","url":"https://stock-news.laohu8.com/highlight/detail?id=1195131681","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195131681?lang=zh_cn&edition=full","pubTime":"2026-06-27 00:15","pubTimestamp":1782490503,"startTime":"0","endTime":"0","summary":"6月27日，因塞特医疗盘中上涨5.84%，报113.78美元/股，成交额1.4亿美元。消息面上，公司宣布其Opzelura乳膏获得欧洲药品管理局人用药品委员会积极意见，推荐批准该药用于对标准局部疗法应答不佳的成人中度特应性皮炎患者。若获欧盟委员会最终批准，Opzelura将成为欧盟首个无类固醇的局部JAK抑制剂。因塞特医疗是一家全球生物制药公司，聚焦血液学、肿瘤学及炎症与自身免疫三大治疗领域的药物发现、开发与商业化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164492035","title":"因塞特医疗股价大涨5.2%，Opzelura皮肤疾病疗法获欧盟积极监管意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1164492035","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164492035?lang=zh_cn&edition=full","pubTime":"2026-06-26 21:55","pubTimestamp":1782482116,"startTime":"0","endTime":"0","summary":"因塞特医疗股价应声上涨5.2%，此前该公司宣布其皮肤疾病治疗药物Opzelura获得了欧盟监管机构的积极意见。这一利好消息提振了市场信心，凸显了该疗法在欧洲市场商业化的关键监管进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","BK4585","BK4550","INCY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128445751","title":"因塞特医疗宣布Opzelura®乳膏获欧盟CHMP积极意见，用于治疗成人中度特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1128445751","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128445751?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:30","pubTimestamp":1782473414,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，其产品Opzelura®（芦可替尼）乳膏在治疗成人中度特应性皮炎方面，已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见。这一进展为Opzelura®在欧盟市场的获批上市铺平了道路，有望为患者提供一种新的局部治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4585","BK4139","BK4550","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104112445","title":"因塞特医疗计划在下期财报中更新财务指引，以反映和解协议的影响——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1104112445","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104112445?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:11","pubTimestamp":1782126718,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，因塞特医疗（Incyte）计划在即将发布的下一份财报中，更新其财务指引，以纳入一项法律和解协议所产生的财务影响。此举旨在向投资者提供更准确、更全面的未来业绩预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","INCY","BK4588","BK4585","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125254391","title":"因塞特医疗日本公司宣布Minjuvi®（Tafasitamab）联合来那度胺获准用于治疗复发或难治性弥漫性大B细胞淋巴瘤成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1125254391","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125254391?lang=zh_cn&edition=full","pubTime":"2026-06-19 14:00","pubTimestamp":1781848817,"startTime":"0","endTime":"0","summary":"因塞特医疗的日本子公司宣布，其药物Minjuvi®（通用名：Tafasitamab）联合来那度胺的治疗方案，已获得监管批准，用于治疗复发或难治性弥漫性大B细胞淋巴瘤的成年患者。该疗法为这一特定患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4532","BK4139","BK4585","BK4550","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174266617","title":"Mirum制药与因塞特医疗公布Zilurgisertib治疗进行性骨化性纤维发育不良的关键2期研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174266617","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174266617?lang=zh_cn&edition=full","pubTime":"2026-06-15 04:36","pubTimestamp":1781469383,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. 与因塞特医疗联合宣布，其候选药物Zilurgisertib在治疗进行性骨化性纤维发育不良的关键性2期PROGRESS研究中，取得了积极的顶线结果。与安慰剂相比，接受Zilurgisertib治疗的患者在关键疾病活动指标上表现出显著改善。安全性方面，Zilurgisertib的耐受性普遍良好，观察到的不良事件与先前研究数据一致。此次积极数据标志着在治疗这种罕见、致残性遗传疾病方面的一个重要进展。两家公司正与监管机构讨论下一步开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4588","INCY","BK4139","MIRM","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175927260","title":"因塞特医疗在EHA 2026公布新阳性数据：INCA033989在骨髓纤维化和原发性血小板增多症患者中实现快速、强劲且持久的临床与分子应答，耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1175927260","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175927260?lang=zh_cn&edition=full","pubTime":"2026-06-13 23:16","pubTimestamp":1781363775,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，在欧洲血液学协会2026年大会上公布的最新积极数据显示，其候选药物INCA033989在治疗骨髓纤维化与原发性血小板增多症患者时，展现出快速、强劲且持久的临床及分子应答，同时表现出良好的耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4588","BK4139","INCY","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101824689","title":"因塞特医疗关键三期FRONTMIND试验数据公布：Tafasitamab组合疗法在2026年EHA大会上展示延长无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1101824689","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101824689?lang=zh_cn&edition=full","pubTime":"2026-06-13 18:01","pubTimestamp":1781344876,"startTime":"0","endTime":"0","summary":"因塞特医疗（Incyte）在2026年欧洲血液学协会（EHA）大会全体会议上公布了其关键性三期FRONTMIND试验的结果。数据显示，tafasitamab（商品名：Monjuvi®/Minjuvi®）联合治疗方案显著延长了患者的无进展生存期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INCY","BK4550","BK4532","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194333066","title":"因塞特医疗将收购星疗法旗下全资子公司维加疗法，拓展其血液学版图至出血性疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1194333066","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194333066?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:02","pubTimestamp":1780916524,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，将收购星疗法旗下的全资子公司维加疗法。此项交易旨在拓展因塞特在血液学领域的产品组合，正式进军出血性疾病治疗市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4588","BK4585","BK4532","BK4139","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117430155","title":"异动解读｜因塞特医疗盘中上涨5.89%，关键临床试验数据积极提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1117430155","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117430155?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:15","pubTimestamp":1780503310,"startTime":"0","endTime":"0","summary":"6月3日，因塞特医疗盘中上涨5.89%，报97.775美元/股，成交额7680.94万美元。消息面上，因塞特医疗近日宣布其关键的Frontmind临床试验数据表明，Tafasitamab联合治疗方案能够显著延长患者的无进展生存期。因塞特医疗是一家全球生物制药公司，从事专有疗法的发现、开发和商业化，研究和商业努力集中在血液学、肿瘤学、炎症和自身免疫三个治疗领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com;investor.incyte.com","stockEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.2252},{"period":"6month","weight":0.2017},{"period":"1year","weight":0.5289},{"period":"ytd","weight":0.2258}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。该公司是一家全球生物制药公司，从事专有疗法的发现、开发和商业化。其研究和商业努力集中在三个治疗领域：血液学、肿瘤学、炎症和自身免疫。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.084187},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.001443},{"month":3,"riseRate":0.424242,"avgChangeRate":-0.039602},{"month":4,"riseRate":0.484848,"avgChangeRate":-0.010488},{"month":5,"riseRate":0.636364,"avgChangeRate":0.060447},{"month":6,"riseRate":0.606061,"avgChangeRate":0.028637},{"month":7,"riseRate":0.545455,"avgChangeRate":0.017026},{"month":8,"riseRate":0.545455,"avgChangeRate":0.019047},{"month":9,"riseRate":0.40625,"avgChangeRate":-0.019519},{"month":10,"riseRate":0.53125,"avgChangeRate":0.026823},{"month":11,"riseRate":0.59375,"avgChangeRate":0.061387},{"month":12,"riseRate":0.59375,"avgChangeRate":0.093713}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}